How to access Evrysdi from the UAE, the named-patient import pathway, 2026
By Reserve Meds · Clinical & regulatory team · Last reviewed 2026-04-23
An Emirati patient, infant, child, or adult, with spinal muscular atrophy (SMA) confirmed by biallelic SMN1 mutations may receive a prescription for Evrysdi (risdiplam) from their treating neurologist. Evrysdi is FDA-approved, developed by Roche and Genentech with PTC Therapeutics and the SMA Foundation, and is an oral once-daily liquid SMN2 splicing modifier. Evrysdi is available in some UAE tertiary centres; where your specific centre does not stock it or where supply is inconsistent, the named-patient pathway is a legitimate bridge.
This guide explains how Reserve Meds supports access in the formulary-gap scenario and where we fit in.
Ask about Evrysdi in UAE
Tell us the medicine and your country. We reply within one business day. On WhatsApp we usually reply the same day.
The clinical situation
Evrysdi is a once-daily oral liquid (or gastrostomy-tube-administered) SMN2 splicing modifier. Weight-based dosing covers paediatric and adult regimens. Eligibility anchors to SMN1 biallelic mutation confirmation and clinical or pre-symptomatic SMA. Baseline assessment is modest compared with gene-therapy or intrathecal regimens. Your neurology team will confirm genotype and plan the monitoring cadence. Because administration is oral, families avoid the logistics of intrathecal visits, a meaningful consideration in the UAE where patient travel between regional centres and tertiary neurology units can be substantial.
Case active and ready to skip the regulatory walkthrough? Ask about a medicine or WhatsApp us.
Is Evrysdi legally importable into the UAE?
Yes, via UAE Ministry of Health and Prevention (MoHAP) named-patient import framework. The mechanism permits a MoHAP-licensed physician to import a medicine not locally registered, or not routinely stocked at a given institution, when (a) the medicine is approved by a recognised reference authority such as the US FDA, (b) no clinically equivalent alternative is available for the patient, (c) the physician accepts clinical responsibility, and (d) chain of custody through a licensed importer is documented.
How the pathway works, step by step
- Consultation with your neurologist. SMN1 confirmation, clinical SMA type, weight documentation, baseline functional assessment, clinical rationale letter.
- Weight-based dosing plan. The prescribing neurologist confirms the regimen.
- MoHAP named-patient application. Your physician files the dossier including rationale, patient reference, and dosing plan.
- US-side sourcing. Reserve Meds coordinates with our US-licensed pharmaceutical wholesale partner to secure Evrysdi from the manufacturer's authorised distribution chain under DSCSA.
- Controlled shipment. Evrysdi ships with appropriate refrigerated logistics and full chain-of-custody documentation to the importer of record.
- Initiation and ongoing refill cadence. Your team initiates daily dosing, monitors motor function and routine safety, and plans refill cycles.
What documentation your physician needs
- Clinical rationale letter confirming SMA diagnosis, SMN1 biallelic status, clinical SMA type, weight, and Evrysdi as the indicated therapy
- Verification of SCFHS medical licence
- SMN1 molecular-testing report
- Weight-based dosing plan
- Multi-month refill schedule
Reserve Meds provides a physician documentation kit bundling the MoHAP templates reviewers expect to see for SMA named-patient files.
Costs and timing
The cost of Evrysdi is weight-based. Medicine price: quote on request. You get a written quote for your case before you commit. International logistics, MoHAP documentation handling, importer-of-record fees, and coordination add incremental cost. Reserve Meds issues a transparent quote at the start of intake.
We give you a written timeline estimate for your case before you commit.
If your clinical situation is time-sensitive, tell us at intake. We triage accordingly.
A culturally-aware note: SMA prevalence in the UAE is elevated by consanguinity and multiple affected children in one extended family is not uncommon. Our case-lead structure supports family-level continuity while each individual case is reviewed on its clinical merits.
Reserve Meds's role
- Sourcing. Through our US-licensed pharmaceutical wholesale partner under DSCSA chain-of-custody.
- Documentation. Regulatory package for your physician and MoHAP review, keyed to the SMA rationale.
- Logistics. Refrigerated shipment to the nominated pharmacy with importer-of-record handling.
- Dedicated case lead. A named point of contact supporting the multi-year daily-dosing treatment horizon and ongoing refill cycles.
What we do not do: we are not the prescriber, we do not practise medicine, and we are not the dispensing pharmacy. All clinical decisions remain with your treating neurologist.
Frequently asked
How does Evrysdi compare with Spinraza? Evrysdi is daily oral; Spinraza is every-four-month intrathecal. Both address the SMN pathway. Your neurologist selects based on anatomy, caregiver preference, and clinical picture.
Can Evrysdi follow Zolgensma? Sequential therapy is not a contraindication; some families use add-on Evrysdi after gene therapy. Your neurologist decides.
How is the liquid stored? Refrigerated at the pharmacy and during shipment; a room-temperature in-use stability window applies once reconstituted, your pharmacy and family will manage.
Will insurance or MoH cover this? Cash-pay is the default for named-patient imports. Some UAE private insurers and MoH rare-disease channels consider case-by-case reimbursement; we supply documentation but do not process claims directly.
Next step
Examples and timings above are composite illustrations drawn from published sources and typical named-patient patterns. Your individual case is assessed by your physician and our clinical-regulatory team; Reserve Meds does not guarantee outcomes or timelines.
Reserve Meds is a digital health company. Medicines are supplied through a US-licensed pharmaceutical wholesale partner. We are not a pharmacy, not the prescriber, and not the manufacturer. Cash-pay. Export-only (US → overseas). Composite case examples. Not medical advice.
Reviewed by the Reserve Meds clinical operations team. Last reviewed: 2026-04-23.
Abu Dhabi and Dubai
This guide covers the whole UAE, including Abu Dhabi and Dubai. At federal level, medicines are regulated by the Emirates Drug Establishment (EDE) and the Ministry of Health and Prevention (MOHAP). MOHAP also issues permits to import medicines for personal use. Hospitals, clinics and doctors are licensed by the health authority of their own emirate: the Department of Health Abu Dhabi (DoH) in Abu Dhabi, and the Dubai Health Authority (DHA) in Dubai.
In practice, the hospital that treats you follows the rules of its own emirate, so the paperwork is prepared for that hospital. Tell us which hospital or doctor is treating you, in Abu Dhabi, Dubai or another emirate, and we prepare the document pack for that route.
Sources: Department of Health Abu Dhabi; Dubai Health Authority, Health Regulation Sector; MOHAP, permit to import medicines for personal use; Simmons & Simmons, UAE pharmaceutical law and the Emirates Drug Establishment.
Frequently asked questions
How can I get Evrysdi in the UAE if it is not approved or available there?
Reserve Meds coordinates US-sourced Evrysdi for patients in the UAE through a legal named-patient pathway, working with your treating doctor. Your treating physician provides the prescription and clinical justification; Reserve Meds prepares the named-patient documentation for the UAE and arranges DSCSA-compliant US sourcing and delivery to your physician or hospital pharmacy.
Can I access Evrysdi in the UAE through a named-patient import?
Often, yes. Named-patient access (sometimes called personal import) is the legal route we use for FDA-approved medicines such as Evrysdi. It is different from compassionate use, which covers investigational medicines through the manufacturer's own program; we do not supply investigational medicines. Eligibility and paperwork depend on the regulator in the UAE, and Reserve Meds maps the specific pathway for each market it coordinates.
Do I need a prescription to access Evrysdi in the UAE through Reserve Meds?
Yes. Reserve Meds is not a pharmacy and does not prescribe. A valid prescription and clinical justification from your treating physician are required, and all clinical decisions remain with your physician.
How does Reserve Meds deliver Evrysdi to a patient in the UAE?
Medicines are supplied through a US-licensed pharmaceutical wholesale partner, and Reserve Meds coordinates delivery of Evrysdi to your treating physician or hospital pharmacy in the UAE, with appropriate handling for the product.
How long does it take, and what does Evrysdi in the UAE cost through Reserve Meds?
After a short intake, the clinical team responds within one business day with case-specific feasibility, an indicative timeline, and a formal written quote. Cost depends on the destination, the prescribed regimen, and the duration of therapy, and is confirmed in writing before anything proceeds.
How do I start a request for Evrysdi in the UAE?
Submit a 60-second intake through the Reserve Meds patient portal, or message our team on WhatsApp. We reply within one business day. On WhatsApp we usually reply the same day.